Presently in the early phases of development, the transcatheter tricuspid valve replacement system is yet to be available for clinical trials
Peijia Medical, in partnership with inQB8 Medical Technologies, has completed the first-in-human implantation of the MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) System.
The device was implanted in a 75-year-old woman having severe torrential tricuspid regurgitation, said Peijia Medical, a China-based medical device company.
Peijia Medical is engaged in making medical devices that can offer treatment solutions for structural heart and neurovascular diseases.
InQB8 Medical Technologies, which is based in the US is a medical device incubator.
Last year, Peijia Medical entered into a partnership with inQB8 Medical Technologies and agreed to acquire the MonarQ TTVR technology from the latter. InQB8 continues to develop the technology on the behalf of its Chinese partner.
InQB8 Medical Technologies cardiac surgeon and co-founder, executive chairman, and CMO Arshad Quadri said: “The MonarQ Transcatheter Tricuspid Valve (TTV) has a unique BioDynamic attachment system that utilises and preserves the heart’s natural motion to secure the implant to the native leaflets, distribute systolic loads, and minimise paravalvular leaks over a wide range of native annulus sizes.”
According to Peijia Medical, the procedure with Trans-Jugular TTVR was carried out on compassionate grounds at a Danish hospital.
Presently in the early phases of development, the MonarQ TTVR system is yet to be available for clinical trials.
Peijia Medical CTO JianFong Tan said: “In the past few years, the need for a Transcatheter Tricuspid Valve Replacement solution has become increasingly clear. As Peijia looks to expand its presence globally and build its structural heart portfolio, our combined investment in inQB8 and the MonarQ TTVR technology was a natural choice.
“The successful first-in-human of MonarQ implantation marks an exciting first step in bringing this life-saving and life-enhancing technology to more and more patients around the world.”